H. Lundbeck AS (LTS:0ND5) EBIT per Share : kr3.11 (TTM As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is H. Lundbeck AS EBIT per Share?

H. Lundbeck AS's EBIT per Share for the three months ended in Mar. 2024 was kr1.29. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was kr3.11.

During the past 12 months, the average EBIT per Share Growth Rate of H. Lundbeck AS was 0.80% per year. During the past 3 years, the average EBIT per Share Growth Rate was -31.50% per year. During the past 5 years, the average EBIT per Share Growth Rate was -39.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for H. Lundbeck AS's EBIT per Share or its related term are showing as below:

LTS:0ND5' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -69.2 Med: 5.5 Max: 255
Current: -31.5

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of H. Lundbeck AS was 255.00% per year. The lowest was -69.20% per year. And the median was 5.50% per year.

LTS:0ND5's 3-Year EBIT Growth Rate is ranked worse than
89.91% of 862 companies
in the Drug Manufacturers industry
Industry Median: 7.4 vs LTS:0ND5: -31.50

H. Lundbeck AS's EBIT for the three months ended in Mar. 2024 was kr1,278 Mil.

H. Lundbeck AS EBIT per Share Historical Data

The historical data trend for H. Lundbeck AS's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

H. Lundbeck AS EBIT per Share Chart

H. Lundbeck AS Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

15.55

10.50

1.75

2.60

3.07

H. Lundbeck AS Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															1.24	0.84	0.90	0.08	1.29

H. Lundbeck AS EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

H. Lundbeck AS's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	3047	/	992.235
=	3.07

H. Lundbeck AS's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	1278	/	992.100
=	1.29

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr3.11

H. Lundbeck AS (LTS:0ND5) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

H. Lundbeck AS EBIT per Share Related Terms

Thank you for viewing the detailed overview of H. Lundbeck AS's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

H. Lundbeck AS (LTS:0ND5) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » H. Lundbeck AS (LTS:0ND5) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

HLBBF:USA HLUBF:USA 0ABR:UK HLUN A:Denmark HLUN B:Denmark LDBA:Germany

Address

Ottiliavej 9, Valby, DNK, 2500

Website

https://www.lundbeck.com

Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system, or CNS, drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.

H. Lundbeck AS (LTS:0ND5) Headlines

No Headlines